MELBOURNE, Australia and SAN FRANCISCO, June 12, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that David Stamler, M.D., Chief Executive Officer will present a company overview at the MST Access ‘Hidden Gems in Life Sciences’ webinar on Thursday, 13 June 2024 in Australia / Wednesday, 12 June 2024 in the United States.
Details are listed below and registration is required.
Webcast details
| AUSTRALIA PARTICIPANTS: | ||
| Date: | Thursday, 13 June 2024 | |
| Time: | 1:30 p.m. AEST (Sydney/Melbourne) | |
| UNITED STATES PARTICIPANTS: | ||
| Date: | Wednesday, 12 June 2024 | |
| Time: | 8:30 p.m. Pacific Time | |
| 11:30 p.m. Eastern Time | ||
To join the presentation, please click the webinar link here.
Investors will have the opportunity to ask questions during the call, at the conclusion of the presentation.
A recording of the webinar will be made available on the Alterity Therapeutics website after the event, which you can access here: www.alteritytherapeutics.com.
About Alterity Therapeutics Limited
Alterity Therapeutics is a clinical stage biotechnology company dedicated to creating an alternate future for people living with neurodegenerative diseases. The Company’s lead asset, ATH434, has the potential to treat various Parkinsonian disorders and is currently being evaluated in two Phase 2 clinical trials in Multiple System Atrophy. Alterity also has a broad drug discovery platform generating patentable chemical compounds to treat the underlying pathology of neurological diseases. The Company is based in Melbourne, Australia, and San Francisco, California, USA. For further information please visit the Company’s website at www.alteritytherapeutics.com.
Authorisation & Additional information
This announcement was authorized by David Stamler, CEO of Alterity Therapeutics Limited.
Investor and Media Contacts:
Australia
Hannah Howlett
This email address is being protected from spambots. You need JavaScript enabled to view it.
+61 450 648 064
U.S.
Remy Bernarda
This email address is being protected from spambots. You need JavaScript enabled to view it.
+1 (415) 203-6386
| Last Trade: | US$3.50 |
| Daily Change: | 0.36 11.46 |
| Daily Volume: | 304,136 |
| Market Cap: | US$30.590M |
December 04, 2024 November 12, 2024 November 06, 2024 October 11, 2024 | |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
